"Special indexing request— modifications being effected;"

- (B) The holder specifically informs FDA of the date on which such modifications are to be effected and submits two printed copies of any revised labeling to be placed in use, and
- (C) All promotional labeling and all drug advertising are promptly revised consistent with modifications made in the labeling on or within the indexed drug package.
- (2) Significant changes. (i) The following modifications to an indexed drug or its labeling may be made only after a request has been submitted to and subsequently granted by FDA:
 - (A) Addition of an intended use.
 - (B) Addition of a species.
- (C) Addition or alteration of an active ingredient.
- (D) Alteration of the concentration of an active ingredient.
- (E) Alteration of dose or dosage regimen.
- (F) Alteration of prescription or over-the-counter status.
- (ii) Each modification described in paragraph (b)(2)(i) of this section must go through the same review process as an original index listing and is subject to the same standards for review.
- (iii) Each submission of a request for a modification described in paragraph (b)(2)(i) of this section should contain only one type of modification unless one modification is actually necessitated by another, such as a modification of dose necessitated by a modification of the concentration of an active ingredient. Submissions relating to addition of an intended use for an existing species or addition of a species should be submitted separately, but each such submission may include multiple additional intended uses and/or multiple additional species.
- (3) Minor changes. All modifications other than those described in paragraphs (b)(1) and (b)(2) of this section including, but not limited to, formulation, labeling, and manufacturing methods and controls (at the same level of detail that these were described in the request for determination of eligibility for indexing) must be submitted as part of the annual indexed drug experience report or as otherwise required by §516.165.

(c) When changes affect the index listing, it will be updated accordingly.

§516.163 Change in ownership of an index file.

- (a) A holder may transfer ownership of a drug's index file to another person.
- (1) The former owner shall submit in writing to FDA a statement that all rights in the index file have been transferred, giving the name and address of the new owner and the date of the transfer. The former owner shall also certify that a complete copy of the following, to the extent that they exist at the time of the transfer of ownership, has been provided to the new owner:
- (i) The request for determination of eligibility:
- (ii) The request for addition to the index:
- (iii) Any modifications to the index listing;
- (iv) Any records and reports under §516.165; and
- (v) All correspondence with FDA relevant to the indexed drug and its index listing
- (2) The new owner shall submit the following information in writing to FDA:
- (i) The date that the change in ownership is effective;
- (ii) A statement that the new owner has a complete copy of all documents listed in paragraph (a)(1) of this section to the extent that they exist at the time of the transfer of ownership;
- (iii) A statement that the new owner understands and accepts the responsibilities of a holder of an indexed drug;
- (iv) The name and address of a new primary contact person or permanent-resident U.S. agent; and
- (v) A list of labeling changes associated with the change of ownership (e.g., a new trade name) as draft labeling, with complete final printed labeling to be submitted in the indexed drug annual report in accordance with §§ 516.161 and 516.165.
- (b) Upon receiving the necessary information to support a change of ownership of a drug's index file, FDA will update its publicly-available listing in accordance with §516.157.